Renaissance Technologies’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-935,958
| Closed | -$37.7M | – | 3174 |
|
|
2026
Q1 | $37.7M | Buy |
935,958
+302,900
| +48% | +$6.53M | 0.06% | 411 |
|
|
2025
Q4 | $15.9M | Sell |
633,058
-89,837
| -12% | -$2.11M | 0.02% | 714 |
|
|
2025
Q3 | $16.4M | Buy |
722,895
+711,907
| +6,479% | +$16.6M | 0.02% | 830 |
|
|
2025
Q2 | $190K | Buy |
+10,988
| New | +$203K | ﹤0.01% | 3183 |
|
|
2025
Q1 | – | Sell |
-271,913
| Closed | -$8.68M | – | 3440 |
|
|
2024
Q4 | $8.68M | Sell |
271,913
-100,418
| -27% | -$3.02M | 0.01% | 1108 |
|
|
2024
Q3 | $10.7M | Buy |
+372,331
| New | +$13.8M | 0.02% | 1009 |
|
|
2023
Q3 | – | Sell |
-138,513
| Closed | -$12.6M | – | 3632 |
|
|
2023
Q2 | $12.6M | Buy |
+138,513
| New | +$12M | 0.02% | 906 |
|
|
2023
Q1 | – | Sell |
-187,413
| Closed | -$9.69M | – | 3955 |
|
|
2022
Q4 | $9.69M | Sell |
187,413
-157,700
| -46% | -$8.36M | 0.01% | 1099 |
|
|
2022
Q3 | $23.6M | Buy |
+345,113
| New | +$20.4M | 0.03% | 596 |
|
|
2021
Q3 | – | Sell |
-20,211
| Closed | -$1.28M | – | 3448 |
|
|
2021
Q2 | $1.28M | Sell |
20,211
-353,302
| -95% | -$18.2M | ﹤0.01% | 2541 |
|
|
2021
Q1 | $16M | Buy |
373,513
+157,200
| +73% | +$7.44M | 0.02% | 909 |
|
|
2020
Q4 | $12.4M | Buy |
+216,313
| New | +$9.15M | 0.01% | 1023 |
|
|
2020
Q1 | – | Sell |
-19,513
| Closed | -$597K | – | 3425 |
|
|
2019
Q4 | $597K | Buy |
+19,513
| New | +$540K | ﹤0.01% | 2830 |
|
|
2019
Q2 | – | Sell |
-26,200
| Closed | -$511K | – | 3528 |
|
|
2019
Q1 | $511K | Buy |
+26,200
| New | +$412K | ﹤0.01% | 2917 |
|
Other funds holding APLS
Renaissance Technologies's APLS Position: Q2 2026 in Review
Renaissance Technologies sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 935,958 shares — an estimated $37.7M sold.
Renaissance Technologies first reported a position in APLS in Q1 2019 and held it in 14 quarters. The position peaked at $37.7M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Renaissance Technologies reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Renaissance Technologies sold 935,958 Apellis Pharmaceuticals shares in Q2 2026, an estimated $37.7M.
- Renaissance Technologies first reported a position in Apellis Pharmaceuticals in Q1 2019 and held it in 14 quarters.
- Renaissance Technologies's Apellis Pharmaceuticals position peaked at $37.7M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.